APO-OXAZEPAM 30 MG
OXAZEPAM : 30 MG · DIN 00402737 · APOTEX INC
Health Canada status: MARKETED
What is APO-OXAZEPAM?
APO-OXAZEPAM 30 MG contains OXAZEPAM : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 00402737, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1979. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-OXAZEPAM used for?
Short-term symptomatic relief of excessive anxiety and tension in anxiety neurosis; relief of symptoms of acute alcoholic withdrawal (agitation and impending delirium tremens).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00402737 |
|---|---|
| Brand name | APO-OXAZEPAM |
| Generic / active ingredient | OXAZEPAM : 30 MG |
| Manufacturer | APOTEX INC |
| Strength | 30 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05BA04 OXAZEPAM |
| AHFS class | 28:24.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1979 |
| Original market date | 1979-12-31 00:00:00 |
How is it administered?
Adults: 30-120 mg daily in divided doses. Elderly/Debilitated: 5 mg once or twice daily. Use lowest effective dose for shortest duration. Taper gradually to discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly specified in the provided text (Section 11 is listed in TOC but content is missing), though standard pharmaceutical storage is implied.
How is it supplied?
Bottles of 100, 500, and 1000 tablets; unit dose packages of 100 (10x10) tablets.
Contraindications
Hypersensitivity to benzodiazepines, infants, history of glaucoma, and myasthenia gravis.
Warnings and precautions
Serious risks of addiction, abuse, misuse, and life-threatening withdrawal. Concomitant use with opioids may cause respiratory depression and death. Risk of falls and fractures.
What can be used instead?
Other Canadian products sharing ATC code N05BA04 OXAZEPAM. 9 of 31 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXAZEPAM | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 00402680 |
| APO-OXAZEPAM | 15 MG | TABLET | APOTEX INC | MARKETED | DIN 00402745 |
| PRO-OXAZEPAM | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00497754 |
| PRO-OXAZEPAM | 15 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00497762 |
| PRO-OXAZEPAM | 30 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00497770 |
| RIVA-OXAZEPAM | 10 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 00568392 |
| RIVA-OXAZEPAM | 15 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 00568406 |
| RIVA-OXAZEPAM | 30 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 00568414 |
| BIO-OXAZEPAM | 10 MG | TABLET | BIOMED PHARMA | CANCELLED POST MARKET | DIN 02247177 |
| BIO-OXAZEPAM | 15 MG | TABLET | BIOMED PHARMA | CANCELLED POST MARKET | DIN 02247178 |
Who else supplies OXAZEPAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OXAZEPAM appears in 158 registered pack listings across 8 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.